Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $465.03M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 8.33M
Average 1.08M
CAPR Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Capricor Therapeutics, Inc.NASDAQ: CAPR
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$3.08M, compared with $1.32M a year earlier. Trailing-twelve-month accounts payables was $1.59M. Over 3 fiscal years it compounded at +70.5% a year.
Context
- Accounts payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$3.08M or moves back toward the trailing-twelve-month quarterly average of $396.86K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 5.98M USD
- Year-over-year change
- +208.3%
- 4-year CAGR
- +56.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.98M | +208.3% |
| FY2024 | 2024-12-31 | 1.94M | +46.4% |
| FY2023 | 2023-12-31 | 1.33M | +9.8% |
| FY2022 | 2022-12-31 | 1.21M | +21.9% |
| FY2021 | 2021-12-31 | 991.17K | — |
Accounts Payables vs competitors
How CAPR compares with its peers on the latest reported figures
- CAPR's LTM Mar 2026 accounts payables of $1.59M is the 7th largest of the 10 companies compared; the peer median is $4.81M.
- Its year-over-year change of -99.4% is the 8th highest of 9, against a peer median of +28.3%.
- Over three fiscal years its annual growth of +70.5% compares with a peer median of -11.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $39.15M | -42.1% | -10.9% | 1.8% | |
| LTM Jun 2026 | $23.17M | +98.6% | — | — | |
| LTM Sep 2026 | $11.71M | -66.8% | — | 1.2% | |
| LTM Sep 2026 | $8.53M | +1178.4% | +79.5% | — | |
| LTM Mar 2026 | $4.81M | +99.3% | — | 6.7% | |
| LTM Mar 2026 | $2.06M | -230.7% | -12.7% | — | |
| LTM Mar 2026 | $1.59M | -99.4% | +70.5% | — | |
| LTM Mar 2026 | $767K | -76.5% | -40.7% | — | |
| LTM Mar 2026 | $752K | +384.8% | — | 13.1% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CAPR) | $4.81M | +28.3% | -11.8% | 1.8% | |
Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Depreciation & Amortization | 245.7K | 533.13K | 1.07M | 1.43M | 1.89M |
| Deferred Income Tax | (310.26K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.97M | 4.46M | 7.39M | 9.77M | 17.23M |
| Change in Working Capital | 182.34K | 28.75M | (11.75M) | (10.78M) | 12.2M |
| Accounts Receivables | (391.75M) | (155.83K) | (9.82M) | 3.5K | 10.31M |
| Inventory | 391.75M | 0 | 0 | 0 | 0 |
| Accounts Payables | 991.17K | 1.21M | 1.33M | 1.94M | 5.98M |
| Other Working Capital | (808.83K) | 27.7M | (3.25M) | (12.73M) | (4.09M) |
| Other Non-Cash Items | 129.73K | 196.01K | (18.24K) | 65.54K | 3.92M |
| Operating Cash Flow | (16.81M) | 4.92M | (25.6M) | (40M) | (69.81M) |
| Capital Expenditures | (1.2M) | (3.36M) | (2.05M) | (1.54M) | (2.9M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (114.22M) | (97.44M) | (208.44M) | (151.39M) |
| Sales of Investments | 0 | 82.51M | 104.6M | 93.8M | 260.6M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.2M) | (35.07M) | 5.11M | (116.18M) | 97.48M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 20.17M | 4.8M | 25.52M | 152.32M | 248.89M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 50.56K | 70.3K | 64.6K | 450.17K | 296 |
| Financing Cash Flow | 20.23M | 4.87M | 25.58M | 152.77M | 248.89M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.22M | (25.28M) | 5.09M | (3.41M) | 276.56M |
| Free Cash Flow | (18.01M) | 1.56M | (27.64M) | (41.53M) | (72.72M) |
Capricor Therapeutics, Inc.
NASDAQ:CAPR
Intrinsic Alpha fair value
Locked
Current Price
$8.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.